Richard J Traystman

Title: The Innovations of Richard J Traystman

Introduction

Richard J Traystman is a notable inventor based in Ruxton, Maryland, who has made significant contributions to the field of medical science. He holds two patents that focus on innovative methods for treating various diseases. His work has implications for both neurodegenerative conditions and metabolic disorders.

Latest Patents

Traystman's latest patents include a dosage form of L-Methionine S-Sulfoximine, which outlines methods for treating diseases that are susceptible to the inhibition of mammalian glutamine synthetase and progressive hyperammonemic encephalopathy. The patent specifies that L-methionine S-sulfoxime should be administered at a dose not to exceed 10 mg/kg body weight, with preferred doses being lower for optimal efficacy. Another significant patent involves the use of selective PARP inhibitors to prevent or treat neurotoxicity. This method addresses neutral tissue damage resulting from ischemia and reperfusion injury or neurodegenerative diseases, allowing for various administration routes including intravenous and oral.

Career Highlights

Throughout his career, Traystman has worked with prestigious institutions, including The Johns Hopkins University and Mso Pharma LLC. His research has focused on developing therapeutic strategies that can significantly improve patient outcomes in critical medical conditions.

Collaborations

Traystman has collaborated with notable colleagues such as Mikael J Eliasson and Kenji Sampei, contributing to a rich exchange of ideas and advancements in their respective fields.

Conclusion

Richard J Traystman's innovative work and patents reflect his commitment to advancing medical science and improving treatment options for patients. His contributions continue to influence the landscape of medical research and therapy.